Clinical study of azithromycin

Yoshiro Sawae, Hiroyasu Misumi, Koji Takaki, Toshiyuki Ishimaru, Masaharu Motomura, Yukio Kumagai, Makoto Katsuno, Nobuyuki Shimono, Hiroshi Inoue, Ikuo Sumita, Takatoshi Inoue

Research output: Contribution to journalArticlepeer-review


A clinical study of azithromycin (AZM), a newly developed oral macrolide antibacterial agent, was performed with the following results. AZM at a dose of 250 or 500 mg was administered once a day for 3 days to 22 patients, including 1 case of pharyngolaryngitis, 4 of acute bronchitis and 17 of pneumonia. The clinical effect was evaluated as excellent in 5, good in 13, poor in 1 and undetermined in 3 cases. Adverse reactions thought to have a causal relationship to AZM included coughing, dyspnea and fever in 1 case and a rigidity of anterior chest in 1 case. However, these symptoms disappeared within 1 month after the administration of AZM. Abnormal laboratory values due to drug administration were observed in 3 cases: increased eosinophils in 2, elevated GOT, GPT, ALP, γ-GTP, CRP and ESR in 1.

Original languageEnglish
Pages (from-to)415-419
Number of pages5
JournalJapanese Journal of Chemotherapy
Publication statusPublished - 1995

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Clinical study of azithromycin'. Together they form a unique fingerprint.

Cite this